"Michael E. Wechsler, MD, is a pulmonologist at National Jewish Health. Dr. Wechsler is in the Division of Pulmonary, Critical Care and Sleep Medicine. My primary research focuses on clinical and translational asthma research, with three main foci of investigation: (i) asthma genetics and personalized medicine; (ii) clinical trials in asthma; and (iii) Churg-Strauss Syndrome. Regarding the genetics of asthma, I have investigated the role of numerous candidate gene polymorphisms in the pathogenesis and management of asthma. I was the Principal Investigator of the Lancet-published, NHLBI-funded Asthma Clinical Research Network’s LARGE trial, which prospectively investigated the effect of beta-adrenergic receptor polymorphisms on the asthmatic response to salmeterol. I also led a recently completed Partners Genetics Enters Medicine Initiative funded trial examining genotype-stratified treatment with anticholinergics vs. beta-agonists (long acting) and exacerbations (GABLE) in asthma (currently undergoing analysis). I was a site Principal Investigator examining the effects of a novel therapy for asthma (bronchial thermoplasty) that utilizes thermal energy to disrupt airway smooth muscle and presented study data to the FDA Medical Advisory panel in 2009, leading to its 2010 FDA approval. I was also awarded an NIH sponsored R21 award to examine the effects of placebo on lung function in asthma, and completed this clinical trial work in more than 40 subjects. Having reported on the importance of using placebos in clinical trials and on the relevance of patient reported outcomes in clinical trials, my NEJM manuscript reset the standard for clinical trial design in this condition. I am a member of the Steering Committee of the NIH-sponsored Asthma Clinical Research Network (ACRN, /Asthmanet), a multi-center asthma clinical trials consortium that has conducted numerous trials that have clarified our understanding of asthma phenotyping and asthma management, laying the foundation for current asthma guidelines. As a member of this consortium, I was the lead investigator who described an association between asthma treatment failures and beta agonist use in African Americans, and am a lead investigator in two separate trials examining race-specific differences in response to asthma therapy. A major focus of my research is elucidating the pathophysiology of Churg-Strauss syndrome, a rare form of eosinophilic vasculitis. I was the first to describe the relationship between CSS and leukotriene modifiers, and between CSS and anti-IgE therapy for asthma. I clinically follow one of the largest cohorts of CSS patients in the country and serve as a referral base for patients with severe asthma from all over the USA. This expertise, and two research awards, have enabled me to recruit the largest cohort of CSS patients, which are serving as the primary test population in a genome-wide association study of CSS. I have examined the role of anti-IL5 in the treatment of CSS patients and have received NIAID R34 funding do a double blind placebo controlled trial in this patient population."